Corporate Advisory

CVC Venture Manager's origin as a successful corporate advisory firm is the genesis for the growth and development of its three business divisions. Over the past decade our experienced team has provided advice and transactional services to wholesale clients acting in a variety of capacities and with mandates including:

  • corporate restructuring
  • ASX IPO listings
  • debt and equity raisings
  • property development and joint ventures
  • mergers, acquisitions and divestements

As a result, the company has extensive and diverse experience in a range of industries and sectors including; health and wellness, nuclear medicine, manufacturing, technology, property project investment and development and ethical investments.

We continue to look for opportunities that meet the requirements of our clients both local and overseas to help expand their businesses in a controlled manner.

Public Listings / IPO's

The company has acted as corporate advisor to ASX listed companies Vita Life Sciences Limited and Cyclopharm Limited.  In it’s role as corporate advisor it successfully listed both companies.  Additional engagements include:

  • leading initial capital raisings
  • secondary raisings
  • joint ventures
  • restructuring
  • divestitures
  • debt arranging

The information below serves only as brief overview of Vita Life Sciences Limited and Cyclopharm Limited.

For more detailed information please click the links below to their corporate websites.

Vita Life Sciences Limited

Vita Life Sciences Ltd is a successful Australian owned pharmaceutical and healthcare company servicing clients throughout Asia and Australia.  The company is listed on the Australian Securities Exchange (ASX).

Vita Life Sciences brands include Herbs of Gold and VitaScience in Australia, and VitaHealth and VitaLife in Asia.  Established since 1947, the group has formulated and sells an extensive range of over the counter pharmaceuticals.

Cyclopharm Limited

Cyclopharm is a radiopharmaceutical company servicing the medical global medical community and is listed on the Australian Securities Exchange (ASX).

The Company’s mission is to enable nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging).  Its customers are nuclear medicine departments located within hospitals and clinics.

© Copyright 2019 CVC Venture Managers